Your browser doesn't support javascript.
loading
Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
Semitala, Fred C; Kadota, Jillian L; Musinguzi, Allan; Nabunje, Juliet; Welishe, Fred; Nakitende, Anne; Akello, Lydia; Bishop, Opira; Patel, Devika; Sammann, Amanda; Nahid, Payam; Belknap, Robert; Kamya, Moses R; Handley, Margaret A; Phillips, Patrick P J; Katahoire, Anne; Berger, Christopher A; Kiwanuka, Noah; Katamba, Achilles; Dowdy, David W; Cattamanchi, Adithya.
Afiliação
  • Semitala FC; Makerere University, Department of Medicine, College of Health Sciences, Kampala, Uganda.
  • Kadota JL; Infectious Diseases Research Collaboration, Kampala, Uganda.
  • Musinguzi A; Makerere University Joint AIDS Program, Kampala, Uganda.
  • Nabunje J; UCSF Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
  • Welishe F; Infectious Diseases Research Collaboration, Kampala, Uganda.
  • Nakitende A; Infectious Diseases Research Collaboration, Kampala, Uganda.
  • Akello L; Infectious Diseases Research Collaboration, Kampala, Uganda.
  • Bishop O; Infectious Diseases Research Collaboration, Kampala, Uganda.
  • Patel D; Infectious Diseases Research Collaboration, Kampala, Uganda.
  • Sammann A; Infectious Diseases Research Collaboration, Kampala, Uganda.
  • Nahid P; The Better Lab, Department of Surgery, University of California, San Francisco, San Francisco, California, United States of America.
  • Belknap R; The Better Lab, Department of Surgery, University of California, San Francisco, San Francisco, California, United States of America.
  • Kamya MR; UCSF Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
  • Handley MA; Denver Health and Hospital Authority and Division of Infectious Diseases, Department of Medicine, University of Colorado, Denver, Colorado, United States of America.
  • Phillips PPJ; Makerere University, Department of Medicine, College of Health Sciences, Kampala, Uganda.
  • Katahoire A; Infectious Diseases Research Collaboration, Kampala, Uganda.
  • Berger CA; Center for Vulnerable Populations at Zuckerberg San Francisco General Hospital and Trauma Center, University of California, San Francisco, San Francisco, California, United States of America.
  • Kiwanuka N; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, United States of America.
  • Katamba A; UCSF Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
  • Dowdy DW; Child Health and Development Center, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
  • Cattamanchi A; UCSF Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
PLoS Med ; 18(12): e1003875, 2021 12.
Article em En | MEDLINE | ID: mdl-34914696
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rifampina / Tuberculose / Terapia Diretamente Observada / Isoniazida / Antituberculosos Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Africa Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rifampina / Tuberculose / Terapia Diretamente Observada / Isoniazida / Antituberculosos Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Africa Idioma: En Ano de publicação: 2021 Tipo de documento: Article